glp-1 substance abuse Not just obesity: receptor agonists advance on addiction The Heavy Price of GLP-1

Nanoparticle-based delivery platforms capable of crossing the BBB could enable targeted regulation of neuronal excitability, offering novel options for managing refractory epilepsy [313315]

At 12 per month, Kind Patches may seem more affordable than prescription medications, but the lack of clinical evidence makes this poor value compared to proven interventions

But it is a lot

An article outlining the effectiveness of GLP-1RAs on obesity

These medications were initially meant for the management of type 2 diabetes but have become popular for weight loss in the past few years

The oral semaglutide offered through MadeMed is a compounded sublingual formulation - it is not the same product, does not use the same proprietary absorption technology, and has not been independently evaluated by the FDA for bioavailability, dosing equivalence, or absorption characteristics relative to the FDA-approved version